Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$3.38 USD
-0.02 (-0.59%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $3.40 +0.02 (0.59%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth A Momentum B VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 37% (145 out of 251)Zacks Sector Rank
Top 13% (2 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.52 | 9.99 |
Current Quarter Estimate | -0.16 | -2.04 | 60.00 |
Year Ago Quarter Estimate | -0.19 | -0.59 | 52.54 |
Next Quarter Estimate | -0.16 | -2.00 | 61.00 |
Next Year Estimate | -1.59 | 6.92 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 10.81 | 9.70 | 17.08 |
Next Year | -140.91 | 13.60 | 8.00 |
Last 5 Years | -241.50 | 5.90 | 8.10 |
Next 5 Years | NA | 22.20 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | NA | 1.87 |
Price/Cash Flow (MRFY) | NA | 9.05 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | -19.76% |
Return on Equity (TTM) | NA | -72.91% |
Debt to Equity (MRQ) | NA | 0.30 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.